指南与共识慢性肾脏病血液净化与透析

KDIGO 2026 CKD贫血指南ERBP评论

KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP).
指南 / 共识 · Nephrol Dial Transplant · 2026-01-01

该文是欧洲肾脏最佳实践组织对KDIGO 2026慢性肾脏病贫血指南的评论,重点评价静脉铁剂与HIF-PHI的新证据,强调个体化治疗、铁剂更积极阈值及ESA首选地位,并指出欧美监管差异。

要点

  • 诊断时需全面评估贫血的其他原因,治疗时机与类型应个体化。
  • 静脉铁剂补充采用更积极的阈值,尤其对血透患者。
  • ESA仍为一线首选,HIF-PHI因心血管安全性及方法学局限未被推荐优先。

核心结论

  • 新指南支持大多数推荐,但欧洲肾脏科医生应结合本地情况、监管批准和新兴证据实施。
  • ESA因心血管安全担忧及HIF-PHI试验方法学局限,仍为推荐的首选一线治疗。

研究设计与样本

  • 欧洲肾脏最佳实践组织对KDIGO 2026慢性肾脏病贫血临床实践指南的评论。

主要发现

  • 新指南纳入了静脉铁剂和HIF-PHI的最新证据,并更新了推荐和实践要点。
  • 新指南强调诊断时全面评估患者以识别促红细胞生成素不足以外的贫血原因。
  • 新指南引入了更积极的静脉铁剂补充阈值,尤其是对血透患者。
  • 评论还讨论了妊娠、性别特异性考量、与SGLT2抑制剂或炎症的相互作用等新指南未涵盖的方面。
  • 评论指出欧洲与美国在HIF-PHI药品批准方面存在区域监管差异。

关键数值与推荐

  • 静脉铁剂补充阈值更积极,尤其针对血透患者。
  • ESA为推荐的首选一线治疗。

临床怎么用

  • 诊断CKD贫血时需全面评估其他贫血原因,而非仅考虑促红细胞生成素不足。
  • 根据患者情况个体化决定治疗时机和类型。
  • 对血透患者可考虑更积极的静脉铁剂补充策略。
  • 实施指南时应考虑本地监管批准和新兴证据。

局限性

  • 评论指出可用HIF-PHI试验存在方法学局限性。
  • 新KDIGO指南未涵盖妊娠、性别特异性考量及与SGLT2抑制剂或炎症的相互作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2026 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Anemia in Chronic Kidney Disease represents a substantial update, coming more than a decade since the previous KDIGO guideline on the topic. This time lapse was necessary in order to accumulate new scientific evidence that was meaningful for an updated guideline. The new guideline now includes updated recommendations and practice points for anaemia management, incorporating recent evidence on intravenous iron therapies and hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs). This European Renal Best Practice commentary critically evaluates and comments on relevant and newer recommendations and practice points, focusing on key aspects from a European perspective. The new guideline emphasizes the need for a comprehensive evaluation of the patient at the time of diagnosis, to identify additional causes of anaemia other than erythropoietin insufficiency. Coherently, the timing and the type of treatment should be individualized. Moreover, it introduces more proactive thresholds for intravenous iron supplementation, especially for haemodialysis patients. Erythropoiesis-stimulating agents are recommended as the preferred first-line therapy due to persisting concerns regarding cardiovascular safety and methodological limitations of available HIF-PHI trials. The commentary includes considerations on special aspects not considered by the new KDIGO guideline, such as pregnancy, gender-specific considerations, and interactions with sodium-glucose cotransporter 2 inhibitors or inflammation. The commentary also highlights regional regulatory differences between European and US drug approvals for HIF-PHIs. While supporting most recommendations, European nephrologists should consider local contexts, regulatory approvals and emerging evidence when implementing these guidelines in clinical practice.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Del Vecchio L, Cases A, Eisenga MF, et al. KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2026. PMID: 41604211. doi:10.1093/ndt/gfag014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。